Biomarkers for the treatment and prognosis of sight-threatening diabetic retinopathy

用于威胁视力的糖尿病视网膜病变的治疗和预后的生物标志物

• 批准号: nhmrc : 1113494
• 负责人: A/Pr Nigel Barnett
• 金额: $ 41.17万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Targeted Calls
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/biomarkers-treatment-prognosis-diabetic-retinopathy/663254
• 关键词: Biomarkers; treatment; prognosis; sight; threatening

Diabetic retinopathy (DR) is a highly specific vascular complication of both type 1 and type 2 diabetes, with prevalence strongly related to the duration of diabetes. Clinic biomarkers of DR have become the basis for preventive medicine. In this project, we aim to evaluate possible biomarkers in both Chinese and Australian diabetic populations at different stages of DR. We will also investigate pathological mechanisms and novel drugs to treat DR in animal models.

糖尿病视网膜病变（DR）是1型和2型糖尿病的高度特异性血管并发症，患病率与糖尿病持续时间密切相关。DR的临床生物标志物已成为预防医学的基础。在这个项目中，我们的目标是评估中国和澳大利亚糖尿病人群在DR不同阶段的可能生物标志物，我们还将在动物模型中研究病理机制和治疗DR的新药。